Cargando…

Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis

PURPOSE: In a retrospective cohort study, we report the current epidemiology of patients with multiple myeloma (MM) and analyze the real-world clinical outcomes of bortezomib-based therapy. MATERIALS AND METHODS: This retrospective study was mainly designed to evaluate the characteristics, treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei-Nung, Chang, Chao-Feng, Chung, Chi-Hsiang, Chien, Wu-Chien, Huang, Tzu-Chuan, Wu, Yi-Ying, Ho, Ching-Liang, Chen, Jia-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748434/
https://www.ncbi.nlm.nih.gov/pubmed/31527921
http://dx.doi.org/10.1371/journal.pone.0222522
_version_ 1783452088605343744
author Liu, Wei-Nung
Chang, Chao-Feng
Chung, Chi-Hsiang
Chien, Wu-Chien
Huang, Tzu-Chuan
Wu, Yi-Ying
Ho, Ching-Liang
Chen, Jia-Hong
author_facet Liu, Wei-Nung
Chang, Chao-Feng
Chung, Chi-Hsiang
Chien, Wu-Chien
Huang, Tzu-Chuan
Wu, Yi-Ying
Ho, Ching-Liang
Chen, Jia-Hong
author_sort Liu, Wei-Nung
collection PubMed
description PURPOSE: In a retrospective cohort study, we report the current epidemiology of patients with multiple myeloma (MM) and analyze the real-world clinical outcomes of bortezomib-based therapy. MATERIALS AND METHODS: This retrospective study was mainly designed to evaluate the characteristics, treatment outcomes, and prognostic factors of patients with MM who received bortezomib-based therapy. We identified 5,726 patients in Taiwan with MM newly diagnosed between 2007 and 2015. Confidential data from the National Health Insurance Research Database (NHIRD) was used under strict guidelines, as it was made available in an electronic format for research purposes. In addition, we analyzed 96 patients who have been diagnosed with MM and were treated at the Tri-Service General Hospital (TSGH) between January 1, 2002, and December 31, 2018. RESULTS: Patients receiving first-line treatment with bortezomib had longer overall survival (OS) compared to those who received non-first-line treatment (p<0.001). In addition, the statistically lowest risk of mortality was when patients received first-line bortezomib followed by an autologous hematopoietic stem cell transplant (adjusted hazard ratio = 0.39, p<0.001). In the TSGH study, the patients were enrolled between January 1, 2002, and December 31, 2018, with an initial diagnosis of MM; there were 96 individuals treated with bortezomib. There was no statistically significant difference in the OS or progression-free survival (PFS) according to the gender, myeloma type, International Staging System stage, or treatment regimen. There was a significant difference in the PFS in patients receiving first-line bortezomib treatment with transplantation compared to those without transplantation (p = 0.021). CONCLUSIONS: Bortezomib as a first-line treatment extended the OS in four-year mortality tracking and lowered the mortality risk according to the NHIRD analysis. In the TSGH analysis, the results indicated that the initial conditions of patients with MM have a lower influence on the OS and PFS after bortezomib-based therapy was administered.
format Online
Article
Text
id pubmed-6748434
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-67484342019-09-27 Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis Liu, Wei-Nung Chang, Chao-Feng Chung, Chi-Hsiang Chien, Wu-Chien Huang, Tzu-Chuan Wu, Yi-Ying Ho, Ching-Liang Chen, Jia-Hong PLoS One Research Article PURPOSE: In a retrospective cohort study, we report the current epidemiology of patients with multiple myeloma (MM) and analyze the real-world clinical outcomes of bortezomib-based therapy. MATERIALS AND METHODS: This retrospective study was mainly designed to evaluate the characteristics, treatment outcomes, and prognostic factors of patients with MM who received bortezomib-based therapy. We identified 5,726 patients in Taiwan with MM newly diagnosed between 2007 and 2015. Confidential data from the National Health Insurance Research Database (NHIRD) was used under strict guidelines, as it was made available in an electronic format for research purposes. In addition, we analyzed 96 patients who have been diagnosed with MM and were treated at the Tri-Service General Hospital (TSGH) between January 1, 2002, and December 31, 2018. RESULTS: Patients receiving first-line treatment with bortezomib had longer overall survival (OS) compared to those who received non-first-line treatment (p<0.001). In addition, the statistically lowest risk of mortality was when patients received first-line bortezomib followed by an autologous hematopoietic stem cell transplant (adjusted hazard ratio = 0.39, p<0.001). In the TSGH study, the patients were enrolled between January 1, 2002, and December 31, 2018, with an initial diagnosis of MM; there were 96 individuals treated with bortezomib. There was no statistically significant difference in the OS or progression-free survival (PFS) according to the gender, myeloma type, International Staging System stage, or treatment regimen. There was a significant difference in the PFS in patients receiving first-line bortezomib treatment with transplantation compared to those without transplantation (p = 0.021). CONCLUSIONS: Bortezomib as a first-line treatment extended the OS in four-year mortality tracking and lowered the mortality risk according to the NHIRD analysis. In the TSGH analysis, the results indicated that the initial conditions of patients with MM have a lower influence on the OS and PFS after bortezomib-based therapy was administered. Public Library of Science 2019-09-17 /pmc/articles/PMC6748434/ /pubmed/31527921 http://dx.doi.org/10.1371/journal.pone.0222522 Text en © 2019 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Liu, Wei-Nung
Chang, Chao-Feng
Chung, Chi-Hsiang
Chien, Wu-Chien
Huang, Tzu-Chuan
Wu, Yi-Ying
Ho, Ching-Liang
Chen, Jia-Hong
Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis
title Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis
title_full Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis
title_fullStr Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis
title_full_unstemmed Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis
title_short Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis
title_sort clinical outcomes of bortezomib-based therapy in taiwanese patients with multiple myeloma: a nationwide population-based study and a single-institute analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748434/
https://www.ncbi.nlm.nih.gov/pubmed/31527921
http://dx.doi.org/10.1371/journal.pone.0222522
work_keys_str_mv AT liuweinung clinicaloutcomesofbortezomibbasedtherapyintaiwanesepatientswithmultiplemyelomaanationwidepopulationbasedstudyandasingleinstituteanalysis
AT changchaofeng clinicaloutcomesofbortezomibbasedtherapyintaiwanesepatientswithmultiplemyelomaanationwidepopulationbasedstudyandasingleinstituteanalysis
AT chungchihsiang clinicaloutcomesofbortezomibbasedtherapyintaiwanesepatientswithmultiplemyelomaanationwidepopulationbasedstudyandasingleinstituteanalysis
AT chienwuchien clinicaloutcomesofbortezomibbasedtherapyintaiwanesepatientswithmultiplemyelomaanationwidepopulationbasedstudyandasingleinstituteanalysis
AT huangtzuchuan clinicaloutcomesofbortezomibbasedtherapyintaiwanesepatientswithmultiplemyelomaanationwidepopulationbasedstudyandasingleinstituteanalysis
AT wuyiying clinicaloutcomesofbortezomibbasedtherapyintaiwanesepatientswithmultiplemyelomaanationwidepopulationbasedstudyandasingleinstituteanalysis
AT hochingliang clinicaloutcomesofbortezomibbasedtherapyintaiwanesepatientswithmultiplemyelomaanationwidepopulationbasedstudyandasingleinstituteanalysis
AT chenjiahong clinicaloutcomesofbortezomibbasedtherapyintaiwanesepatientswithmultiplemyelomaanationwidepopulationbasedstudyandasingleinstituteanalysis